Ro partners with Amgen to study barriers to obesity care, GLP-1 access – One America News Network

0
153

By Reuters
January 13, 2026 – 7:23 AM PST

REUTERS/Deena Beasley/File Photo

(Reuters) – U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen (AMGN.O) to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 therapies.

The study will use data from Ro’s direct-to-consumer platform to track insurance coverage as well as prior authorization requirements for GLP-1 drugs such as Novo Nordisk’s (NOVOb.CO) Ozempic and Eli Lilly’s (LLY.N) Zepbound.

Weight-loss drugs have reshaped obesity care, but many patients still struggle to obtain them because of coverage gaps, Ro said.

While drugmakers built their own direct-to-consumer channels, companies such as Noom, Ro and WeightWatchers (WW.O) are playing a growing role in connecting patients with virtual prescribers and helping…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here